This HTML5 document contains 88 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n4http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01148/identifier/wikipedia/
n30http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01148/identifier/pharmgkb/
n17http://linked.opendata.cz/resource/mesh/concept/
n20http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01148/identifier/kegg-compound/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01148/identifier/pubchem-compound/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01148/identifier/pubchem-substance/
n21http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB01148/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n25http://linked.opendata.cz/resource/drugbank/drug/DB01148/identifier/national-drug-code-directory/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
n16http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n29http://www.drugs.com/cdi/
n13http://linked.opendata.cz/resource/drugbank/property/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01148/identifier/chemspider/
n14http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB01148/identifier/chebi/
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01148
rdf:type
n5:Drug
n5:description
A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem]
n5:dosage
n15:271B494B-363D-11E5-9242-09173F13E4C5 n15:271B494C-363D-11E5-9242-09173F13E4C5 n15:271B494D-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:indication
For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.
owl:sameAs
n19:DB01148 n21:DB01148
dcterms:title
Flavoxate
adms:identifier
n11:PA164781386 n12:Flavoxate n22:3237 n23:DB01148 n24:5088 n25:0574-0115-01 n26:C07809 n27:3354 n28:46505138
n5:mechanismOfAction
Flavoxate acts as a direct antagonist at muscarinic acetylcholine receptors in cholinergically innervated organs. Its anticholinergic-parasympatholytic action reduces the tonus of smooth muscle in the bladder, effectively reducing the number of required voids, urge incontinence episodes, urge severity and improving retention, facilitating increased volume per void.
n5:packager
n20:271B4946-363D-11E5-9242-09173F13E4C5 n20:271B4947-363D-11E5-9242-09173F13E4C5 n20:271B4944-363D-11E5-9242-09173F13E4C5 n20:271B4945-363D-11E5-9242-09173F13E4C5 n20:271B4942-363D-11E5-9242-09173F13E4C5 n20:271B4943-363D-11E5-9242-09173F13E4C5 n20:271B4941-363D-11E5-9242-09173F13E4C5 n20:271B4940-363D-11E5-9242-09173F13E4C5 n20:271B493E-363D-11E5-9242-09173F13E4C5 n20:271B493F-363D-11E5-9242-09173F13E4C5 n20:271B493C-363D-11E5-9242-09173F13E4C5 n20:271B493D-363D-11E5-9242-09173F13E4C5
n5:routeOfElimination
57% of the flavoxate HCl was excreted in the urine within 24 hours.
n5:synonym
Flavoxate 2-Piperidinoethyl 3-methylflavone-8-carboxylate Flavoxatum 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate Flavoxate HCI Flavoxato 2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate beta-Piperidinoethyl 3-methylflavone-8-carboxylate
n5:toxicity
The oral LD50 for flavoxate HCl in rats is 4273 mg/kg. The oral LD50 for flavoxate HCl in mice is 1837 mg/kg. Symptoms of overdose include convulsions, decreased ability to sweat, (warm, red skin, dry mouth, and increased body temperature), hallucinations, increased heart rate and blood pressure, and mental confusion.
n8:hasAHFSCode
n30:86-12-00
n5:foodInteraction
Food may reduce irritation. Take without regard to meals.
n5:salt
n5:synthesisReference
Da Re, P.; U.S. Patent 2,921,070; January 12, 1960; assigned to Recordati-Laboratorio Farmacologico SPA, Italy.
n16:hasConcept
n17:M0008552
foaf:page
n4:flavoxate.htm n14:uri1471.shtml n29:flavoxate.html
n5:IUPAC-Name
n13:271B4952-363D-11E5-9242-09173F13E4C5
n5:InChI
n13:271B4958-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n13:271B4957-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n13:271B4954-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n13:271B4955-363D-11E5-9242-09173F13E4C5
n5:SMILES
n13:271B4956-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n13:271B4967-363D-11E5-9242-09173F13E4C5 n13:271B4950-363D-11E5-9242-09173F13E4C5
n5:logP
n13:271B4951-363D-11E5-9242-09173F13E4C5 n13:271B494E-363D-11E5-9242-09173F13E4C5 n13:271B4969-363D-11E5-9242-09173F13E4C5
n5:logS
n13:271B494F-363D-11E5-9242-09173F13E4C5
n5:pKa
n13:271B496A-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:G04BD02
n5:H-Bond-Acceptor-Count
n13:271B495E-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n13:271B495F-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n13:271B4959-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n13:271B495A-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n13:271B495C-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n13:271B495B-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n13:271B495D-363D-11E5-9242-09173F13E4C5
n5:absorption
Well absorbed from gastrointestinal tract.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
15301-69-6
n5:category
n5:containedIn
n7:271B494A-363D-11E5-9242-09173F13E4C5 n7:271B4948-363D-11E5-9242-09173F13E4C5 n7:271B4949-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n13:271B4963-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n13:271B4965-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n13:271B4966-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n13:271B4968-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n13:271B4962-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n13:271B4961-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n13:271B4964-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n13:271B4953-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n13:271B4960-363D-11E5-9242-09173F13E4C5